Datopotamab Deruxtecan (DS-1062; Dato-DXd) (CAS: 2238831-60-0)
Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate (ADC) developed for targeted cancer therapy. It combines a humanized monoclonal antibody that targets the TROP2 protein, which overexpresses in many cancers, with deruxtecan, a potent topoisomerase I inhibitor.
Key Features:
- Targeted Therapy: The antibody specifically binds to TROP2 on cancer cells, delivering the cytotoxic drug directly to the tumor.
- Cytotoxic Payload: Deruxtecan disrupts DNA replication, leading to cell death in cancer cells.
- Enhanced Efficacy: The ADC approach ensures higher concentrations of the cytotoxic drug at the tumor, improving effectiveness while minimizing systemic toxicity.
Applications:
- Non-Small Cell Lung Cancer (NSCLC): Investigated for treating advanced or metastatic NSCLC with TROP2 overexpression.
- Breast Cancer: Targets HER2-negative breast cancers with TROP2 overexpression.
- Other TROP2-Positive Cancers: Studied for various solid tumors expressing TROP2.
Handling and Storage:
- Storage: Store at -20°C, away from light and moisture.
- Handling: Follow standard laboratory precautions when handling the reagent.
This ADC offers a targeted approach to treat cancers that overexpress TROP2, providing potent and focused treatment to the tumor while sparing healthy tissues.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.